Mountain Valley MD Holdings Inc
CNSX:MVMD
Mountain Valley MD Holdings Inc
Mountain Valley MD Holdings, Inc. engages in the implementation of its patented Quicksome oral delivery technologies across molecules in nutraceutical, vaccine and pharmaceutical drug applications. The company is headquartered in Vaughan, Ontario. The company went IPO on 2018-03-02. Through its subsidiary, Mountain Valley MD Inc., the Company is engaged in implementing and licensing of its technologies to global pharmaceutical, vaccine and nutraceutical third parties. Its technology include Quicksome oral drug formulation and delivery technologies. The Company’s Quicksome desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into product formats that are consumed orally. The company is also developing other technologies, including Quicksol solubility formulation technology, and pending dose sparing adjuvant.
Mountain Valley MD Holdings, Inc. engages in the implementation of its patented Quicksome oral delivery technologies across molecules in nutraceutical, vaccine and pharmaceutical drug applications. The company is headquartered in Vaughan, Ontario. The company went IPO on 2018-03-02. Through its subsidiary, Mountain Valley MD Inc., the Company is engaged in implementing and licensing of its technologies to global pharmaceutical, vaccine and nutraceutical third parties. Its technology include Quicksome oral drug formulation and delivery technologies. The Company’s Quicksome desiccation technology utilizes advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into product formats that are consumed orally. The company is also developing other technologies, including Quicksol solubility formulation technology, and pending dose sparing adjuvant.
